Loading...

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

Although high rates of complete hematologic and cytogenetic remission have been observed in patients with chronic phase chronic myeloid leukemia (CML) treated with imatinib, a short duration of response with eventual emergence of imatinib resistance has also been reported in a subset of CML patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Martinelli, Giovanni, Iacobucci, Ilaria, Soverini, Simona, Palandri, Francesca, Castagnetti, Fausto, Rosti, Gianantonio, Baccarani, Michele
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2007
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2721303/
https://ncbi.nlm.nih.gov/pubmed/19707322
Tags: Add Tag
No Tags, Be the first to tag this record!